

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Loratadine 5 mg/5 ml Syrup

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1ml of syrup contains 1mg loratadine.

Each 1 ml of syrup also contains the following excipients:

0.11 g glycerol (E422)

0.11 g propylene glycol

0.6 g sucrose

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Oral Solution

Colour free, Peach flavour

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Loratadine 5mg/5ml Syrup is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticarial in adults and children over the age of 2 years.

4.2 Posology and method of administration

Posology

Adults and children over 12 years of age:
10ml (10mg) of the syrup once daily.

Paediatric population

Children 2 to 12 years of age are dosed by weight:

Body weight more than 30kg: 10ml (10mg) of the syrup once daily;

Body weight 30kg or less: 5ml (5mg) of the syrup once daily.

Efficacy and safety of Loratadine 5mg/5ml Syrup in children under 2 years of age has not been established.

Patients with severe liver impairment

Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine. An initial dose of 10mg every other day is recommended for adults and children weighing more than 30kg, and for children weighing 30kg or less, 5ml (5mg) every other day is recommended.

Patients with severe renal impairment

No dosage adjustments are required in the elderly or in patients with renal insufficiency.

Elderly

No dosage adjustments are required in the elderly.

Formatted: Font color: Auto

Method of administration

For oral administration.

4.3 Contraindications

Loratadine 5mg/5ml Syrup is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients in this formulation (see section 6.1).

4.4 Special warnings and precautions for use

Loratadine 5mg/5ml Syrup should be administered with caution in patients with severe liver impairment (see section 4.2).

This medicinal product contains sucrose; patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

The administration of Loratadine 5mg/5ml Syrup should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.

4.5 Interaction with other medicinal products and other forms of interaction

When administered concomitantly with alcohol, Loratadine 5mg/5ml Syrup has no potentiating effects as measured by psychomotor performance studies.

Formatted: Font color: Auto

Potential interaction may occur with all known inhibitors of CYP3A4 or CYP2D6 resulting in elevated levels of loratadine (see section 5.2), which may cause an increase in adverse events.

Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Formatted: Font color: Auto

Paediatric population

Interaction studies have only been performed in adults.

Formatted: Font color: Auto

4.6 Fertility, pregnancy and lactation

Pregnancy

A large amount of data on pregnant women (more than 1000 exposed outcomes) indicate no malformative nor feto/neonatal toxicity of loratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Loratadine 5mg/5ml Syrup during pregnancy.

Breast-feeding

Loratadine is excreted in breast milk, therefore the use of loratadine is not recommended in breast-feeding women.

Fertility

There are no data available on male and female fertility.

Formatted: Font color: Auto

4.7 Effects on ability to drive and use machines

In clinical trials that assessed driving ability, no impairment occurred in patients receiving loratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

4.8 Undesirable effects

a. Summary of the safety profile

Formatted: Bullets and Numbering

In clinical trials involving adults and adolescents in a range of indications including AR and CIU, at the recommended dose of 10mg daily, adverse reactions with loratadine were reported in 2% of patients in excess of those treated with the placebo. The most frequent adverse reactions reported in excess of placebo were somnolence (1.2%), headache (0.6%), increased appetite (0.5%) and insomnia (0.1%).

b. Tabulated list of adverse reactions

Formatted: Font color: Auto

Formatted: Bullets and Numbering

The following adverse reactions reported during the post-marketing period are listed in the following table by System Organ Class. Frequencies are defined as very common (> 1/10), common (> 1/100 to < 1/10), uncommon (> 1/1,000 to < 1/100), rare (> 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

<u>System Organ Class</u>	<u>Frequency</u>	<u>Adverse Reaction</u>
<u>Immune system disorders</u>	<u>Very rare</u>	<u>Hypersensitivity reactions(including angioedema and anaphylaxis)</u>
<u>Nervous system disorders</u>	<u>Very rare</u>	<u>Dizziness, Convulsion</u>
<u>Cardiac disorders</u>	<u>Very rare</u>	<u>Tachycardia, palpitation</u>
<u>Gastrointestinal disorders</u>	<u>Very rare</u>	<u>Nausea, dry mouth, gastritis</u>
<u>Hepato-biliary disorders</u>	<u>Very rare</u>	<u>Abnormal hepatic function</u>
<u>Skin and subcutaneous tissue disorders</u>	<u>Very rare</u>	<u>Rash, alopecia</u>
<u>General disorders and administration site conditions</u>	<u>Very rare</u>	<u>Fatigue</u>
<u>Investigations</u>	<u>Not known</u>	<u>Weight increased</u>

c. Paediatric population

In clinical trials in a paediatric population children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue (1%).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9 Overdose

Overdosage with loratadine increased the occurrence of anticholinergic symptoms. Somnolence, tachycardia, and headache have been reported with overdoses.

In the event of overdose, general symptomatic and supportive measures are to be instituted and maintained for as long as necessary. Administration of activated charcoal as a slurry with water may be attempted. Gastric lavage may be considered. Loratadine is not removed by haemodialysis and it is not known if loratadine is removed by peritoneal dialysis. Medical monitoring of the patient is to be continued after emergency treatment.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: anti histamines – H₁ antagonist, ATC code: R06A X13.

Loratadine, the active ingredient in Loratadine 5mg/5ml Syrup, is a tricyclic antihistamine with selective, peripheral H₁-receptor activity.

Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage. During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms.

Loratadine has no significant H₂-receptor activity. It does not inhibit norepinephrine uptake and has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.

5.2 Pharmacokinetic properties

After oral administration, loratadine is rapidly and well absorbed and undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite-desloratadine (DL)- is pharmacologically active and responsible for a large part of the clinical effect. Loratadine and DL achieve maximum plasma concentrations (T_{max}) between 1-1.5 hours and 1.5-3.7 hours after administration, respectively.

Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Loratadine is highly bound (97% to 99%) and its active metabolite moderately bound (73% to 76%) to plasma proteins.

In healthy subjects, plasma distribution half-lives of loratadine and its active metabolite are approximately 1 and 2 hours, respectively. The mean elimination half lives in healthy adult subjects were 8.4 hours (range=3 to 20 hours) for loratadine and 28 hours (range-8.8 to 92 hours for the major active metabolite).

Approximately 40% of the dose is excreted in the urine and 42% in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27% of the dose is eliminated in the urine

during the first 24 hours. Less than 1% of the active substance is excreted unchanged in active form, as loratadine or DL.

The bioavailability parameters of loratadine and of the active metabolite are dose proportional.

The pharmacokinetic profile of loratadine and its metabolites is comparable in healthy adult volunteers and in healthy geriatric volunteers.

Concomitant ingestion of food can delay slightly the absorption of loratadine but without influencing the clinical effect.

In patients with chronic renal impairment, both the AUC and peak plasma levels (C_{max}) increased for loratadine and its metabolite as compared to the AUCs and peak plasma levels (C_{max}) of patients with normal renal function. The mean elimination half-lives of loratadine and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of loratadine or its active metabolite in subjects with chronic renal impairment.

In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (C_{max}) of loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.

Loratadine and its active metabolite are excreted in the breast milk of lactating women.

5.3 Preclinical safety data

Preclinical data reveal no special hazard based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.

In reproductive toxicity studies, no teratogenic effects were observed. However, prolonged parturition and reduced viability of offspring were observed in rats at plasma levels (AUC) 10 times higher than those achieved with clinical doses.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Propylene glycol

Glycerol (E422)

Sodium Benzoate (E211)

Citric Acid Monohydrate

Sucrose

Purified Water

Peach Flavour

6.2 Incompatibilities

None known

6.3 Shelf life

Shelf life before opening - 2 years

Shelf life after opening – 6 months

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Bottle made from Type III Amber Glass with a tamper evident child resistant closure having a polypropylene outer layer and a polyethylene inner layer. This product is provided with a measuring device.

Pack Sizes: 60 ml, 100 ml and 150 ml.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Pinewood Laboratories Limited *trading as* Pinewood Healthcare

Ballymacarbry

Clonmel

Co. Tipperary

Ireland

8 MARKETING AUTHORISATION NUMBER(S)

PL 04917/0067

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

11/07/2011

10 DATE OF REVISION OF THE TEXT

29/07/2023